Cargando…
The Prognostic Value of Postoperative Lymph Node Ratio in Gastric Adenocarcinoma Patients Treated With Neoadjuvant Chemotherapy
Objective In this study, we aimed to investigate the prognostic value of postoperative lymph node ratio (LNR)in locally advanced gastric cancer (GC) patients receiving neoadjuvant chemotherapy (NACT). Methods LNR was calculated as the ratio of positive LNs to the total LNs removed. The receiver oper...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8140955/ https://www.ncbi.nlm.nih.gov/pubmed/34046274 http://dx.doi.org/10.7759/cureus.14639 |
_version_ | 1783696283505000448 |
---|---|
author | Sakin, Abdullah Atci, Muhammed M Aldemir, Mehmet Naci Akagündüz, Baran Şahin, Suleyman Arıcı, Serdar Secmeler, Saban Cihan, Sener |
author_facet | Sakin, Abdullah Atci, Muhammed M Aldemir, Mehmet Naci Akagündüz, Baran Şahin, Suleyman Arıcı, Serdar Secmeler, Saban Cihan, Sener |
author_sort | Sakin, Abdullah |
collection | PubMed |
description | Objective In this study, we aimed to investigate the prognostic value of postoperative lymph node ratio (LNR)in locally advanced gastric cancer (GC) patients receiving neoadjuvant chemotherapy (NACT). Methods LNR was calculated as the ratio of positive LNs to the total LNs removed. The receiver operating characteristic (ROC) curve was plotted to estimate the cut-off value of LNR for recurrence. The area under the curve of LNR was 0.714 (95% CI: 0.604-0.825, p<0.001) with 60% sensitivity and >0.255 with 76% specificity. Patients were grouped as group I (≤0.255) and group II (>0.255). Results In this study, 157 GC patients were included (39.5% female and 60.5% male). Of the patients, 97 (61.8%) were in group I and 60 (38.2%) were in group II. Disease‑free survival (DFS) was not reached in group I, and it was 16 months in group II (p<0.001). Overall survival (OS) was 58 months in group I and 28 months in group II (p>0.001). In multivariate analysis, lymphovascular invasion, neoadjuvant response, adjuvant treatment, and LNR were found to be the factors associated with DFS and OS (p<0.05). Conclusion In our study, it was observed that LNR can predict survival rates better than LN staging. |
format | Online Article Text |
id | pubmed-8140955 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Cureus |
record_format | MEDLINE/PubMed |
spelling | pubmed-81409552021-05-26 The Prognostic Value of Postoperative Lymph Node Ratio in Gastric Adenocarcinoma Patients Treated With Neoadjuvant Chemotherapy Sakin, Abdullah Atci, Muhammed M Aldemir, Mehmet Naci Akagündüz, Baran Şahin, Suleyman Arıcı, Serdar Secmeler, Saban Cihan, Sener Cureus Oncology Objective In this study, we aimed to investigate the prognostic value of postoperative lymph node ratio (LNR)in locally advanced gastric cancer (GC) patients receiving neoadjuvant chemotherapy (NACT). Methods LNR was calculated as the ratio of positive LNs to the total LNs removed. The receiver operating characteristic (ROC) curve was plotted to estimate the cut-off value of LNR for recurrence. The area under the curve of LNR was 0.714 (95% CI: 0.604-0.825, p<0.001) with 60% sensitivity and >0.255 with 76% specificity. Patients were grouped as group I (≤0.255) and group II (>0.255). Results In this study, 157 GC patients were included (39.5% female and 60.5% male). Of the patients, 97 (61.8%) were in group I and 60 (38.2%) were in group II. Disease‑free survival (DFS) was not reached in group I, and it was 16 months in group II (p<0.001). Overall survival (OS) was 58 months in group I and 28 months in group II (p>0.001). In multivariate analysis, lymphovascular invasion, neoadjuvant response, adjuvant treatment, and LNR were found to be the factors associated with DFS and OS (p<0.05). Conclusion In our study, it was observed that LNR can predict survival rates better than LN staging. Cureus 2021-04-22 /pmc/articles/PMC8140955/ /pubmed/34046274 http://dx.doi.org/10.7759/cureus.14639 Text en Copyright © 2021, Sakin et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Oncology Sakin, Abdullah Atci, Muhammed M Aldemir, Mehmet Naci Akagündüz, Baran Şahin, Suleyman Arıcı, Serdar Secmeler, Saban Cihan, Sener The Prognostic Value of Postoperative Lymph Node Ratio in Gastric Adenocarcinoma Patients Treated With Neoadjuvant Chemotherapy |
title | The Prognostic Value of Postoperative Lymph Node Ratio in Gastric Adenocarcinoma Patients Treated With Neoadjuvant Chemotherapy |
title_full | The Prognostic Value of Postoperative Lymph Node Ratio in Gastric Adenocarcinoma Patients Treated With Neoadjuvant Chemotherapy |
title_fullStr | The Prognostic Value of Postoperative Lymph Node Ratio in Gastric Adenocarcinoma Patients Treated With Neoadjuvant Chemotherapy |
title_full_unstemmed | The Prognostic Value of Postoperative Lymph Node Ratio in Gastric Adenocarcinoma Patients Treated With Neoadjuvant Chemotherapy |
title_short | The Prognostic Value of Postoperative Lymph Node Ratio in Gastric Adenocarcinoma Patients Treated With Neoadjuvant Chemotherapy |
title_sort | prognostic value of postoperative lymph node ratio in gastric adenocarcinoma patients treated with neoadjuvant chemotherapy |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8140955/ https://www.ncbi.nlm.nih.gov/pubmed/34046274 http://dx.doi.org/10.7759/cureus.14639 |
work_keys_str_mv | AT sakinabdullah theprognosticvalueofpostoperativelymphnoderatioingastricadenocarcinomapatientstreatedwithneoadjuvantchemotherapy AT atcimuhammedm theprognosticvalueofpostoperativelymphnoderatioingastricadenocarcinomapatientstreatedwithneoadjuvantchemotherapy AT aldemirmehmetnaci theprognosticvalueofpostoperativelymphnoderatioingastricadenocarcinomapatientstreatedwithneoadjuvantchemotherapy AT akagunduzbaran theprognosticvalueofpostoperativelymphnoderatioingastricadenocarcinomapatientstreatedwithneoadjuvantchemotherapy AT sahinsuleyman theprognosticvalueofpostoperativelymphnoderatioingastricadenocarcinomapatientstreatedwithneoadjuvantchemotherapy AT arıcıserdar theprognosticvalueofpostoperativelymphnoderatioingastricadenocarcinomapatientstreatedwithneoadjuvantchemotherapy AT secmelersaban theprognosticvalueofpostoperativelymphnoderatioingastricadenocarcinomapatientstreatedwithneoadjuvantchemotherapy AT cihansener theprognosticvalueofpostoperativelymphnoderatioingastricadenocarcinomapatientstreatedwithneoadjuvantchemotherapy AT sakinabdullah prognosticvalueofpostoperativelymphnoderatioingastricadenocarcinomapatientstreatedwithneoadjuvantchemotherapy AT atcimuhammedm prognosticvalueofpostoperativelymphnoderatioingastricadenocarcinomapatientstreatedwithneoadjuvantchemotherapy AT aldemirmehmetnaci prognosticvalueofpostoperativelymphnoderatioingastricadenocarcinomapatientstreatedwithneoadjuvantchemotherapy AT akagunduzbaran prognosticvalueofpostoperativelymphnoderatioingastricadenocarcinomapatientstreatedwithneoadjuvantchemotherapy AT sahinsuleyman prognosticvalueofpostoperativelymphnoderatioingastricadenocarcinomapatientstreatedwithneoadjuvantchemotherapy AT arıcıserdar prognosticvalueofpostoperativelymphnoderatioingastricadenocarcinomapatientstreatedwithneoadjuvantchemotherapy AT secmelersaban prognosticvalueofpostoperativelymphnoderatioingastricadenocarcinomapatientstreatedwithneoadjuvantchemotherapy AT cihansener prognosticvalueofpostoperativelymphnoderatioingastricadenocarcinomapatientstreatedwithneoadjuvantchemotherapy |